Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED)

Carcinoma, Non-Small-Cell Lung Clinical Trial

Official title:

A Phase 2 Study of Temozolomide (SCH 52365) in Subjects With Advanced Aerodigestive Tract Cancers Selected for Methylation of O6-Methyl-Guanine-DNA Methyltransferase (MGMT) Promoter

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00423150
• Other study ID #: P04273
• Status: Terminated
• Phase: Phase 2
• First received: November 30, 2006
• Last updated: October 30, 2014
• Start date: January 2007
• Est. completion date: June 2009

Study information

• Verified date: October 2014
• Source: Merck Sharp & Dohme Corp.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This study is proposed to evaluate the efficacy and safety of temozolomide, an oral anti-cancer agent, in a participant population selected for a biomarker. Participants with colorectal cancer, non-small-cell lung cancer, head and neck cancer, or esophageal cancer will be included.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 86
• Est. completion date: June 2009
• Est. primary completion date: June 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participants must be at least 18 years of age.

• Participants must have metastatic colorectal cancer (CRC), recurrent or metastatic head & neck (H&N) or esophageal cancer, or locally advanced, inoperable, or metastatic non-small cell lung cancer (NSCLC).

• Participants must have a tumor sample or a blood sample tested positive for the presence of the biomarker.

• Participants may have up to 3 prior regimens for CRC, up to 3 prior regimens for NSCLC, up to 2 prior regimens for H&N and esophageal cancer.

• Participants must have at least one measurable lesion.

• Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

• Participants must have adequate hematologic, renal, and liver functions.

• Participants must be able to take the study medication capsules orally, or through a feeding tube without the capsules being opened.

• Participants of childbearing potential must agree to use a medically accepted method of contraception.

Exclusion Criteria:

• Participants who have received treatment for a second malignancy within 1 year before screening, and are considered to be at risk of relapse within 1 year after screening.

• Participants with unstable or progressing central nervous system (CNS) metastasis. Participants with known CNS metastasis may be included if a) the subject is asymptomatic, b) there is no requirement for steroids or antiseizure medications, or the required doses are stable, and c) there is no associated midline shift or (in the opinion of the investigator) significant edema.

• Participants who received prior temozolomide or dacarbazine treatment

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Colorectal Neoplasm
• Colorectal Neoplasms
• Esophageal Neoplasm
• Esophageal Neoplasms
• Head and Neck Neoplasm
• Head and Neck Neoplasms
• Neoplasms

Intervention

Drug:
• Temozolomide
Temozolomide capsules 150 mg/m^2 daily on a 7-day on / 7-day off schedule for each 28-day cycle, until disease progression, intolerable toxicity, or withdrawal of consent.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Merck Sharp & Dohme Corp.

References & Publications (1)

Hochhauser D, Glynne-Jones R, Potter V, Grávalos C, Doyle TJ, Pathiraja K, Zhang Q, Zhang L, Sausville EA. A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA me — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Tumor Responses (Complete and Partial Response)	Tumor response rate was based on Response Evaluation Criteria in Solid Tumors (RECIST).; Complete Response (CR): Disappearance of all target lesions.; Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.	From start of treatment until participant's disease progression, intolerable toxicity or death, which ever comes first	No